Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS View Full Press Release Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Travere Therapeutics Provides Corporate Update and 2025 Outlook